🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.

Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.

Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.

Our Chief Medical Officer, Tomasz, and Director of Clinical Operations, Karen, in Paris next week for COMy.

Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: linkedin.com/feed/update/ur…

Tomasz and Kris in Madrid for #EHA2024. CellCentric’s novel oral drug, inobrodib, in Phase II trials for multiple myeloma.

Delighted to confirm $35m from RA Capital Mgmt, plus support from the American Cancer Society’s BrightEdge. lnkd.in/dCQqFTag Endpoints coverage: lnkd.in/dZUP6TbU

Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: cellcentric.com/press-release/…

Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!

Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.

Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma

We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.

We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. American Cancer Society Cancer Action Network

We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: cellcentric.com/press-release/…

2 weeks to go…! We’ll be sharing latest clinical data at #ASH24, San Diego. New Drug for Multiple Myeloma. See: cellcentric.com/press-release/…

Delighted to have such a strong network of advisors supporting inobrodib’s drug development. See: cellcentric.com/team/

We will be at #ASH24, presenting latest Phase II data: New Drug in Multiple Myeloma, Dec 9th. Novel MoA, additive to, complementing existing treatments.

We will be sharing latest clinical data on Monday 5pm PT at #ASH24, San Diego. Inobrodib, our novel oral drug, new MoA, to treat multiple myeloma.

PRESS RELEASE: cellcentric.com/press-release/… Emma Searle at #ASH24 shared latest positive inobrodib clinical data in treating multiple myeloma.